The announcement of Shanghai No.1 Pharmacy indicates that the company expects a net income attributable to the owner of the parent company of 115 million yuan to 145 million yuan in the first half of 2024, a year-on-year increase of 150.93% to 216.39%. Deducting non-recurring gains and losses, the net income is expected to be 6 million yuan to 8 million yuan, a year-on-year decrease of 65.89% to 74.42%. The growth in performance is mainly due to the compensation for house requisition received by the company and its subsidiaries.
第一医药：预计2024年上半年净利润同比增加150.93%到216.39%
Shanghai No.1 Pharmacy expects a year on year increase in net income of 150.93% to 216.39% in the first half of 2024.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.